Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.52 |
| ▸ | NPY1R | P25929 | 10/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.52 |
| ▸ | NPY2R | P49146 | 6/20 | 0.52 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29883702 | 0.93 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2RF2 | |
| SCHEMBL30592735 | 0.91 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29461982 | 0.89 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29461991 | 0.88 | C5AR1 (0.54) | — | |
| SCHEMBL29540550 | 0.88 | C5AR1 (0.54) | — | |
| SCHEMBL31680267 | 0.86 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30092917 | 0.86 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2RF2 | |
| SCHEMBL29936549 | 0.85 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30427476 | 0.85 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30092922 | 0.85 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190859-A1 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190859-A1 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | TNNI3, TNNT2, FABP3 | NPY4R 2427/4885NPY1R 1544/4885NPY5R 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.